BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal ...

Chemoprevention has emerged as a promising strategy to reduce cancer incidence by using pharmacologic agents that interrupt the carcinogenesis process. This review discusses emerging insights and ...

People carrying BRCA1 and BRCA2 gene mutations are at high risk of developing breast and ovarian cancer. Researchers have found that changes occur in the immune cells of breast tissue in carriers of ...

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find. Patients who underwent major surgery for 8 cancer types experienced an increased rate of ...